Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients

J Infect. 2022 Feb;84(2):248-288. doi: 10.1016/j.jinf.2021.08.034. Epub 2021 Aug 23.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Viral / immunology
  • Antibody Formation
  • COVID-19*
  • Humans
  • Imatinib Mesylate
  • SARS-CoV-2*

Substances

  • Antibodies, Viral
  • Imatinib Mesylate